Fig. 5

Lovastatin did not improve novel object recognition in Ube3a^−/+ and disrupted novel object recognition in Ube3a^+/+ mice. A In the novel object recognition task, vehicle treated Ube3a^+/+ mice investigated the novel object for significantly longer than the familiar object, as expected. * p < 0.05, t-test of novel versus familiar. When treating Ube3a^+/+ mice with any dose of lovastatin, the investigation time of the novel object was reduced, and no preference for investigating the novel object was observed. B Ube3a^−/+ mice showed no preference for investigating the novel object when treated with vehicle or any dose of lovastatin. * p < 0.05, t-test of novel versus familiar object investigation. C Using discrimination index to measure the varying doses of lovastatin on Ube3^+/+ and Ube3a^−/+ mice, no significant cognitive effect was observed, via one-way ANOVA, followed by Dunnett’s posthoc comparisons. D Using preference ratio to measure the varying doses of lovastatin on Ube3a^+/+ and Ube3a^−/+ mice, no significant cognitive effect was observed, via one-way ANOVA, followed by Dunnett’s post hoc comparisons